To study the pharmacokinetics of vigabatrin in a patient affected with tuberous sclerosis who developed major agitation and aggression, while receiving vigabatrin orally (1.5 g every 12 h) and in whom impaired renal function was diagnosed. Methods The patient received vigabatrin (0.5 g day −1 ). A pharmacokinetic study of the S(+) and R(−) enantiomers of vigabatrin was performed before and during dialysis. Plasma concentrations were measured at 0, 1, 2, 3, 4, 6, 12, 18 and 24 h by a specific GCMS assay. Results Before dialysis, the maximum and minimun plasma concentrations of vigabatrin at steady-state were lower for the S(+) than for the R(−) enantiomer, while the apparent oral clearance was higher for the S(+) than for the R(−) enantiomer (2.97 vs 0.48 l h −1 ). In addition, the haemodialysis clearance was similar for the two enantiomers (4.96 vs 5.15 l h −1 ).
Introduction Methods
Vigabatrin (c-vinyl GABA) is a selective, enzyme-activated, Patient irreversible inhibitor of GABA-transaminase, the enzyme catalysing the catabolism of the neurotransmitter GABA [1,
The patient, born in 1980, was affected with tuberous sclerosis, diagnosed at the age of 3 months when she 2]. Vigabatrin produces a dose-related increase in CSF GABA [3] . It reduces the frequency of partial seizures by at developed partial seizures, with secondary generalized tonicclonic seizures. From 1980 to 1993, she received various least 50% in about half of adult and paediatric patients with drug-resistant epilepsy [4] [5] [6] [7] .
anti-epileptic drugs, including carbamazepine alone or in combination with phenobarbitone, with phenytoin or Vigabatrin is a racemic mixture of two enantiomers S(+) and R(−), the S(+) enantiomer being the active compound.
clobazam, without complete remisson of seizures. She also presented with behavioural disturbances with social disability. The drug is reported not to be protein bound and to be eliminated unchanged by renal excretion [8, 9] . The
In 1993, vigabatrin (3 g day −1 ) was added to carbamazepine (600 mg day −1 ). The frequency of seizures decreased to 2 pharmacokinetics of the two enantiomers are very similar [10, 11] .
to 3 per week. Sixteen months later, the patient complained of fatigue and presented with nausea and vomiting and she Here, we describe a 15 year old epileptic patient, who was treated with vigabatrin for more than 6 months at the developed important additional behavioural changes, while routine laboratory tests revealed that serum creatinine was standard dose of 3 g day . At admission, her weight was 64 kg, clinical examination revealed major agitation and aggression, alterdrug was performed before the decision to dialyse and during a dialysis session. The pharmacological data demonnating with phases of confusion and drowsiness. Laboratory tests included haemoglobin, 5.4 g dl
, serum creatinine strated major differences in the disposition of the two enantiomers.
848 mmol l −1 and creatinine clearance was 10 ml min cysts and end-stage renal failure was attributed to tuberous E. Jacqz-Aigrain et al. 
Drug analysis
Blood samples (1 ml) were collected in heparinized tubes, centrifuged and kept frozen (−20°C) until analysis. The enantiomers of vigabatrin were measured using a specific gas chromatography mass spectrometry procedure [10] . The coefficients of variation were less than 13.8% at all concentrations from 0.5 to 50 mg ml −1 for both enantiomers.
Pharmacokinetics in end-stage renal failure Blood samples were collected before drug administration and at 1, 2, 3, 4, 6, 12, 18 and 24 h after administration. Pharmacokinetic analysis was performed with use of compartment independent methods. The oral apparent clearance was determined using the following relationship:
Time ( interval between two administrations, AUC is the area under the plasma concentration time curve between two the duration of sampling was limited to 24 h, the terminal half-life could only be estimated for the S(+) enantiomer administrations at steady-state.
and it was 16 h. It is certainly much longer for the R(−) enantiomer. Haemodialysis plasma clearance Haemodialysis clearance (CLHD) was calculated using the following relationship:
The patient underwent haemodialysis sessions of 4 h duration. The haemodialysis clearance was measured while CL HD =[(Q P ×C A )−(Q P −Q U )×C V ]/C A the patient was receiving 0.5 g every 24 h (7.8 mg kg −1 day −1 ) and is presented in Table 1 . The amount of R(−) where C A and C V are the concentrations in the arterial and venous segments of the blood flow loop, Q P is the enantiomer recovered in the dialysate over 4 h was 351 mg, while it was 102 mg for the S(+) enantiomer. The average plasma flow rate (equal to: blood flow rate× (1−haematocrit)) and Q U is the ultrafiltrate flow rate.
haemodialysis clearance was similar for the two enantiomers: 4.96 l h −1 for the S(+) and 5.15 l h −1 for the R(−)
enantiomer. Results
The pharmacokinetic parameters of the S(+) and R(−) Discussion enantiomers of vigabatrin were determined at steady-state, after 22 days of treatment with an oral dose of 0.5 g day
Vigabatrin, a structural analogue of the inhibitory neurotransmetter gamma-aminobutyric acid (GABA), is a racemic (Table 1 and Figure 1 ). The C min values were 2.2 and 17.4 mg l −1 for the S(+) and R(−) enantiomers respectmixture of two enantiomers S(+) and R(−). The S(+) enantiomer is pharmacologically active while the R(−) ively. The C max value of the S(+) enantiomer was lower than that of the R(−) enantiomer (5.9 vs 27.8 mg l −1 ) and enantiomer is inactive. Vigabatrin is normally well tolerated and the incidence of the difference (C max value−C min value) was 3.7 and 10.4 mg l −1 for the S(+) and R(−) enantiomers respectside-effects appears low. Among them, the most frequent in children are agitation and hyperkinesia, estimated to occur ively. In addition, the apparent oral clearance was much higher for the S(+) than for the R(−) enantiomer. Because in 15 to 25% of epileptic patients [5] . It usually appears reducing the dose. It mainly involves patients with mental
